Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - Viracta Therapeutics, Inc. | snss-ex311_8.htm |
| EX-10.1 - EX-10.1 SVB DEFERRAL AGREEMENT - Viracta Therapeutics, Inc. | snss-ex101_90.htm |
| EX-4.1 - EX-4.1 - Viracta Therapeutics, Inc. | snss-ex41_109.htm |
| 10-Q - Q1 2020 10-Q - Viracta Therapeutics, Inc. | snss-10q_20200331.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Sunesis Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Periodic Report”), I, Dayton Misfeldt, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
|
1. |
The Periodic Report, to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and |
|
2. |
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: May 7, 2020 |
|
/s/ DAYTON MISFELDT |
|
|
|
Dayton Misfeldt Interim Chief Executive Officer (Principal Executive and Principal Financial Officer) |
|
|
|
|
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sunesis Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.